SOLICITATION NOTICE
B -- Testosterone Supplementation in Relation to Prostate Cancer and Cardiovascular Disease: Enabling Online Doubly-Robust Estimation Models of the Health Core Integrated Research Database
- Notice Date
- 8/3/2014
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP42601-83
- Archive Date
- 9/4/2014
- Point of Contact
- Gwennifer K. Epps, Phone: 240-276-5445, Terry Galloway, Phone: 240-276-5384
- E-Mail Address
-
eppsg@mail.nih.gov, gallowaytl@mail.nih.gov
(eppsg@mail.nih.gov, gallowaytl@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Epidemiology and Biostatistics Program (EBP), plans to provide access via STARx software to de-identified study populations drawn from fully-insured members' data contained within the Health Core Integrated Research Database (HIRD), on a sole source basis with Consolidated Research Inc., 321 South Beverly Drive, Suite M, Beverly Hills, CA 90212-4303 This process will be processed in accordance with simplified acquisitions procedures as stated in FAR Part 13 13.106-1(b)(1) and is exempt for the requirements of FAR Part 6. The North American Industry Classification System code is 541990 and the business size standard is $14.0 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. Period of performance will be for 12 months from the date of award. The Epidemiology and Biostatistics Program (EBP) conducts independent and collaborative epidemiologic and biostatistical investigations to identify the distribution, characteristics, and causes of cancer in human populations. The Program also develops biostatistical methods for population-based studies. In carrying out its research activities, EBP utilizes national and regional statistics, field studies involving questionnaires and biologic specimen collections, and collaborative research with other governmental agencies, academic centers and private sector groups. The Epidemiology and Biostatistics Program has for decades had an active program of assessing the effect of use of specific medications and subsequent cancer risks (increased or decreased). Since an in-depth assessment can be complex and resource consumptive, NCI have long sought a data resource that would have sufficient information to screen for drugs that show evidence of such effects, in order to decide which ones warrant more comprehensive data collection efforts. Such a resource would need to have comprehensive prescription data for a large population, and systematic follow-up information for subsequent diagnoses of cancer and other outcomes. No such resource has existed nor has been available for access until recently. As a result, the EBP plans to procure on a contract with Consolidated Research Inc., t o provide access via STARx software to de-identified study populations drawn from fully-insured members' data contained within the Health Core Integrated Research Database (HIRD) which includes enrollment files, pharmacy claims, medical claims (with diagnostic and procedure codes), and outpatient laboratory results data. These databases include large numbers of testosterone supplement users, PDE5I users, and non-users which will enable NCI to assess associations between testosterone supplementation in relation to the outcomes of non-fatal myocardial infarction and prostate cancer. Consolidated Research, Inc.'s has been used in previous analysis of testosterone supplementation and non-fatal myocardial infarction (Finkle et al., PLOS ONE, 2014) conducted by EBP. And, in order to ensure EBP's external validation study is directly comparable to the current study NCI must use the same vendor to ensure the same state-of-the-art models for analysis are being used. Also, given the size and structure of the data as well as the required protections, the entire dataset cannot be directly shared with external organizations. To overcome such barriers and to enable state-of-the-art statistical analyses, Consolidated Research, Inc. have developed a software package-STARx-which can compute risk estimates based on odds-of-treatment weighting and unweighted methods. Importantly this package enables remote access to the company-stored dataset. Based on these facts, Consolidated Research, Inc. is uniquely qualified to serve the Government's requirements. This is not a solicitation for competitive quotations. However, if any interested party especially small business, believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on, August 20, 2014. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (240) 276-5401 or emailed to Gwennifer Epps, Contracting Officer at eppsg@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA), through sam.gov. No collect calls will be accepted. Please reference solicitation number N02CP42601-83 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP42601-83/listing.html)
- Place of Performance
- Address: National Cancer Institute/NIH, Rockville, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN03447728-W 20140805/140804020453-df55457b5c6e6f8d6be6d99e11630441 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |